Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells

Inclusion Criteria:

• Type 2 Diabetes
• Oral antidiabetic therapy
• Age 35 - 70
• 6,5%< HbA1c ≤ 9%
• Ability of subject to understand character and individual consequences of clinical trial
• Written informed consent must be available before enrollment in the trial
• For women with childbearing potential, adequate contraception (Pearl Index < 1%, e.g. birth control pill) and negative blood pregnancy test
• 6,5%< HbA1c ≤ 9%
• Ability of subject to understand character and individual consequences of clinical trial
• Written informed consent must be available before enrollment in the trial
• For women with childbearing potential, adequate contraception (Pearl Index < 1%, e.g. birth control pill) and negative blood pregnancy test

Exclusion Criteria:

• MODY
• Malignant disease
• Hematopoietic disorders
• Impairment of renal function (Serum creatinine > 1,5mg/dl)
• autoimmune disease
• treatment with immunosuppressive drugs
• Psychiatric disease
• Myocardial ischemia during previous 6 month
• Acute coronary syndrome
• pAVK IIb, III, IV (Fontaine-Ratschow)
• Erythropoietin treatment
• Glitazone treatment during two weeks before inclusion
• Insulin treatment during two weeks before inclusion
• Pregnancy and lactation
• History of hypersensitivity to the investigational product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational product
• Participation in other clinical trials and observation period of competing trials, respectively
• No subject will be allowed to enroll in this trial more than once.